Authors :
Dinesh Kumar G; Harshidha. D; Benita. S; Mousigan. M.V; Dinesh. T
Volume/Issue :
Volume 7 - 2022, Issue 11 - November
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3uHdmGh
DOI :
https://doi.org/10.5281/zenodo.7420605
Abstract :
Obesity and diabetes prevalence are often
referred to as the "twin epidemics" and are becoming a
more widespread issue, particularly in developed
countries. Advanced therapeutic strategies are therefore
required. Tirzepatide, known as "twincretin", is a "firstclass" drug and the only agonist of glucagon-like peptide1 (GLP-1) and glucose-dependent peptide (GIP) receptors,
which can significantly reduce blood sugar. levels and
improved insulin sensitivity, as well as more than 20%
reduction in body weight and improved lipid metabolism.
This new antidiabetic drug is a synthetic peptide analog of
human GIP hormone with a linkage to C20 fatty acid
moiety that, through acylation process, can bind to
albumin to deliver a single dose, by a single subcutaneous
injection, once a week, consistent with its half-life of
approximately five days. The "twincretin" heralded in an
era of tremendously important and alluring dual therapy
choices for diabetes and obesity, as well as advanced
management of closely associated cardiometabolic
settings, which are the primary global cause of illness,
disability, and mortality. Here, we outline the salient
features of tirzepatide's synthesis, structure, and action
while also considering its benefits and drawbacks.
Additionally, we briefly examine the progression of clinical
research and the evolution of this type of medicinal
medication.
Keywords :
Diabetes, Insulin, Incretins, Obesity, Tirzepatide, Twincretin.
Obesity and diabetes prevalence are often
referred to as the "twin epidemics" and are becoming a
more widespread issue, particularly in developed
countries. Advanced therapeutic strategies are therefore
required. Tirzepatide, known as "twincretin", is a "firstclass" drug and the only agonist of glucagon-like peptide1 (GLP-1) and glucose-dependent peptide (GIP) receptors,
which can significantly reduce blood sugar. levels and
improved insulin sensitivity, as well as more than 20%
reduction in body weight and improved lipid metabolism.
This new antidiabetic drug is a synthetic peptide analog of
human GIP hormone with a linkage to C20 fatty acid
moiety that, through acylation process, can bind to
albumin to deliver a single dose, by a single subcutaneous
injection, once a week, consistent with its half-life of
approximately five days. The "twincretin" heralded in an
era of tremendously important and alluring dual therapy
choices for diabetes and obesity, as well as advanced
management of closely associated cardiometabolic
settings, which are the primary global cause of illness,
disability, and mortality. Here, we outline the salient
features of tirzepatide's synthesis, structure, and action
while also considering its benefits and drawbacks.
Additionally, we briefly examine the progression of clinical
research and the evolution of this type of medicinal
medication.
Keywords :
Diabetes, Insulin, Incretins, Obesity, Tirzepatide, Twincretin.
